Clene Inc (CLNN)
NASDAQConsumer StaplesBiotechnologySnapshot 2026-09-09
$3.72+2.76%
Close 2026-09-09 · 1-day change
NASDAQConsumer StaplesBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Clene plans to submit a New Drug Application for CNM-Au8 in Q3 2026. The company has extended its operating runway into Q4 2026. Net loss decreased from $9.2M in 2025-Q4 to $8.1M in 2026-Q1, showing some expense control progress.
Clene remains loss-making with negative EPS guidance of -$2.65 per share in 2026. Cash flow is still negative and the company faces volatile management and sector headwinds. The company missed earnings in recent quarters.
The market currently prices Clene as a loss-making clinical-stage company with no clear revenue growth or profitability. There is no consensus revenue growth or fair value data, reflecting uncertainty. Our view differs by focusing on the upcoming NDA submission as a key catalyst.
Breaks if: NDA submission delayed beyond Q3 2026
Submit a New Drug Application for CNM-Au8 under the accelerated approval pathway for ALS in the third quarter of 2026.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth thesis, as CLNN is navigating a volatile management landscape and loss-making status. The current state reflects a cautious approach due to recent earnings misses and high near-term risk.
The market appears to be pricing in elevated expectations given CLNN's expensive valuation compared to peers. Recent financial performance has not met industry standards, suggesting that the stock may be reflecting a gap between current performance and future potential.
Fundamentals are likely to remain under pressure in the near term, especially given the high probability of an earnings miss. Management is making some progress in managing cash flow and extending the operating runway, but overall performance has been weak.
The long-term thesis hinges on several factors, including the successful submission of the NDA for CNM-Au8 and potential sector momentum from leading Consumer Staples companies. Additionally, inflation trends and guidance from key competitors will play a significant role in shaping future performance.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company reported better earnings per share. This indicates improved cash flow management. However, it also missed earnings expectations. The latest earnings miss raises concerns about future performance.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Management consistently communicated plans to submit an NDA for CNM-Au8 under the accelerated approval pathway in Q3 2026, supported by FDA meeting minutes confirming the data may support submission. The trajectory is delivering as the NDA submission is expected imminently.
“Clene expects to submit a New Drug Application for CNM-Au8 in early fourth quarter of 2026.”
“Clene expects to submit an NDA for CNM-Au8 under the accelerated approval pathway in the third quarter of 2026.”
“FDA stated proposed data may support submission and review of an NDA under accelerated approval pathway; Clene intends to submit NDA in Q3 2026.”
Breaks if: Net loss increases above $9.2M or fails to improve over next 4 quarters
Control operating expenses and cash usage to extend financial sustainability.
Stated as a priority in 3 of last 3 quarters. Net cash used in operating activities decreased from $9.8 million in first half 2025 to $7.1 million in first half 2026. R&D expenses decreased from $4.995 million in 2025-Q2 to $3.5 million in 2026-Q2. Management is delivering moderate progress in managing cash flow and operating expenses.
“Research and development expenses were $3.5 million for the quarter ended June 30, 2026, compared to $3.5 million for the same period in 2025.”
“Research and development expenses were $0.3 million for the quarter ended March 31, 2026, compared to $1.5 million for the same period in 2025.”
“Operating expenses and cash used in operations reported with focus on managing costs.”
Breaks if: Operating runway falls short of Q4 2026
Maintain sufficient cash and resources to fund operations through the fourth quarter of 2026.
Stated as a priority in 3 of last 3 quarters. Cash and cash equivalents increased from $5.2 million at 2025-Q4 to $9.7 million at 2026-Q2. Management expects this cash position will provide operating runway through late Q4 2026, indicating delivery on this priority.
“Clene expects that its resources as of June 30, 2026, will provide operating runway through late fourth quarter 2026.”
“Clene expects that its resources as of March 31, 2026, will provide operating runway into the fourth quarter of 2026.”
“Sufficient cash to fund operations into the fourth quarter of 2026.”
Over the next 1 to 3 years, CLNN's outlook is uncertain, with significant risks and mixed management execution. Not investment advice.